We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Isogenica, Cresset Group and Biolauncher Secure Funding from UK’s Technology Strategy Board
News

Isogenica, Cresset Group and Biolauncher Secure Funding from UK’s Technology Strategy Board

Isogenica, Cresset Group and Biolauncher Secure Funding from UK’s Technology Strategy Board
News

Isogenica, Cresset Group and Biolauncher Secure Funding from UK’s Technology Strategy Board

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Isogenica, Cresset Group and Biolauncher Secure Funding from UK’s Technology Strategy Board"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Isogenica and Biolauncher, Cambridge UK together with Cresset Group, Welwyn Garden City UK have announced funding from the Technology Strategy Board, the UK’s innovation agency, for a £1M project to develop a highly-scalable approach to small molecule drug discovery.

The funding enables the consortium to develop an integrated platform to identify diverse small molecules active against drug targets using very large peptide libraries to explore chemical space.

The consortia’s objective is to demonstrate that this platform provides a new scalable approach to the early stage drug discovery challenges that is rapid, cost effective and applicable to intracellular, extracellular and membrane bound drug targets.

The process will use Isogenica’s libraries to select a population of diverse binding peptides against a biological target. These peptides will be analyzed using novel structural bioinformatics already developed by Biolauncher to identify their active conformation.

This three-dimensional template will be used to generate a field based pharmacophore that Cresset will use to identify small molecule drug-like medicinal chemistry starting points.

Individually the component technologies have been used in over 170 drug discovery projects to date.

“The diversity of the chemical libraries in corporate collections can be quite limited and so the percentage of chemical space represented is small. Isogenica’s peptide libraries are designed to be structurally very diverse and sample a much greater volume of chemical space. Also, in addition to acting as a structural template, there is a high probability of finding binding peptides which have immediate utility as reagents for probing the target biology and supporting the drug development process” commented Rowan Gardner, who is leading the consortia’s Business Development activity.

“By working with diverse populations of binding peptides it is possible to determine which residues are contributing to the binding and infer their active conformations. Coupling Isogenica’s massive screening libraries with Cresset’s small molecule bioisostere discovery tools offer the possibility to bridge biologics directly into small molecule chemistry” added Kevin Mathews, CEO of Isogenica.

Advertisement